To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma
Status:
Recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
This is a randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint
bioequivalence study to compare the efficacy and safety of generic fluticasone propionate
inhalation aerosol USP 44 mcg (Glenmark Pharmaceuticals Ltd) to Flovent HFA (fluticasone
propionate inhalation aerosol) 44 mcg (GSK group of companies) in treatment of patients with
bronchial asthma.